Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM707 Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT04913337Phase 2Active, not recruiting
- Sponsor
- NGM Biopharmaceuticals
- Start
- Jun 2021
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Bispecific Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of NGM707 in mesothelioma, glioblastoma (GBM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), melanoma, sponsored by NGM Biopharmaceuticals. Started Jun 2021; status: active, not recruiting.
02
Drugs
NGM707
03
Conditions
mesotheliomaglioblastoma (GBM)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT04913337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913337.